The differential effect of endocytic trafficking on EGFR has therapeutic implications as Clathrin inhibition can divert a tyrosine kinase inhibitor (TKI)-resistant form of EGFR from Clathrin-mediated endocytosis and recycling to pinocytosis and degradation in non-small cell lung carcinoma (Ménard et al., 2018). This evidence concerns the gene EGFR and non-small cell lung carcinoma.